Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – Here’s What Happened

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $26.05, but opened at $27.28. Capricor Therapeutics shares last traded at $27.41, with a volume of 142,259 shares trading hands.

Wall Street Analyst Weigh In

CAPR has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 13th. B. Riley Financial raised their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday. Piper Sandler reaffirmed an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Finally, Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the company an “overweight” rating in a research note on Friday, March 13th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $48.36.

Capricor Therapeutics Stock Up 1.5%

The firm has a market capitalization of $1.64 billion, a PE ratio of -12.23 and a beta of 0.39. The firm’s 50 day moving average price is $30.50 and its two-hundred day moving average price is $28.06.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). On average, sell-side analysts anticipate that Capricor Therapeutics, Inc. will post -0.75 earnings per share for the current fiscal year.

Insider Activity

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00. Following the sale, the chief financial officer owned 8,223 shares in the company, valued at $260,669.10. This represents a 75.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karimah Es Sabar sold 7,529 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total value of $240,928.00. Following the transaction, the director owned 7,529 shares in the company, valued at $240,928. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 172,529 shares of company stock valued at $5,302,440 over the last 90 days. Insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV acquired a new stake in Capricor Therapeutics in the 1st quarter valued at approximately $44,000. ACT Capital Management LLC acquired a new position in Capricor Therapeutics during the 4th quarter worth $43,000. GoalVest Advisory LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth $59,000. Allworth Financial LP grew its stake in shares of Capricor Therapeutics by 5,021.5% in the fourth quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 3,264 shares in the last quarter. Finally, State of Wyoming increased its holdings in shares of Capricor Therapeutics by 76.0% during the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 1,913 shares during the period. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.